Funding for this research was provided by:
Japan Society for the Promotion of Science (21H02649)
Core Research for Evolutional Science and Technology (JP171024167)
Japan Agency for Medical Research and Development (22ama121018)
Article History
Received: 17 June 2022
Accepted: 29 August 2022
First Online: 21 September 2022
Declarations
:
: Sumio Ohtsuki is a full professor at Kumamoto University and is also a director of Proteomedix Frontiers. The other authors declare that they have no conflict of interest.